Floatz logo

ANTIBODY-DRUG CONJUGATE ANTI-TIM-1-VCMMAE CDX-014

Clear-cell Renal Cell Carcinoma

Celldex Therapeuticsantibody_drug_conjugatePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

116 Active assets in the Clear-cell Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
gw786034
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
Girentuximab
Massachusetts General Hospital
Phase 3BB
CLOSTRIDIUM BUTYRICUM MIYAIRI 588
City of Hope Medical Center
Phase 3BB
gw786034
Academic and Community Cancer Research United
Phase 4BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 2BB

View all 50 →

Same molecule, other indications

ANTIBODY-DRUG CONJUGATE ANTI-TIM-1-VCMMAE CDX-014 is also rated in:

papillary renal cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
kidney neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
Ovarian Clear Cell CarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →